Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Beam Therapeutics (BEAM) EBT: 2019-2025

Historic EBT for Beam Therapeutics (BEAM) over the last 7 years, with Sep 2025 value amounting to -$112.7 million.

  • Beam Therapeutics' EBT fell 16.61% to -$112.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$421.8 million, marking a year-over-year decrease of 194.01%. This contributed to the annual value of -$376.7 million for FY2024, which is 187.21% down from last year.
  • Per Beam Therapeutics' latest filing, its EBT stood at -$112.7 million for Q3 2025, which was down 3.16% from -$109.3 million recorded in Q2 2025.
  • In the past 5 years, Beam Therapeutics' EBT registered a high of $144.2 million during Q4 2023, and its lowest value of -$200.4 million during Q1 2021.
  • In the last 3 years, Beam Therapeutics' EBT had a median value of -$96.5 million in 2023 and averaged -$77.0 million.
  • Its EBT has fluctuated over the past 5 years, first tumbled by 621.93% in 2021, then surged by 485.99% in 2023.
  • Quarterly analysis of 5 years shows Beam Therapeutics' EBT stood at -$64.7 million in 2021, then spiked by 42.28% to -$37.3 million in 2022, then spiked by 485.99% to $144.2 million in 2023, then slumped by 162.67% to -$90.4 million in 2024, then fell by 16.61% to -$112.7 million in 2025.
  • Its last three reported values are -$112.7 million in Q3 2025, -$109.3 million for Q2 2025, and -$109.4 million during Q1 2025.